Greenwich LifeSciences (GLSI) Competitors $10.68 +0.13 (+1.23%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. ZVRA, TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, and PRMEShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Zevra Therapeutics (ZVRA), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Its Competitors Zevra Therapeutics Tyra Biosciences Taysha Gene Therapies Opthea Bicycle Therapeutics Kura Oncology Septerna Abivax Maze Therapeutics Prime Medicine Zevra Therapeutics (NASDAQ:ZVRA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Do analysts prefer ZVRA or GLSI? Zevra Therapeutics currently has a consensus price target of $23.71, indicating a potential upside of 98.28%. Greenwich LifeSciences has a consensus price target of $39.00, indicating a potential upside of 265.17%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ZVRA or GLSI? In the previous week, Zevra Therapeutics had 12 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 12 mentions for Zevra Therapeutics and 0 mentions for Greenwich LifeSciences. Zevra Therapeutics' average media sentiment score of 0.73 beat Greenwich LifeSciences' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Zevra Therapeutics Positive Greenwich LifeSciences Neutral Is ZVRA or GLSI more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -226.78%. Zevra Therapeutics' return on equity of -201.05% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-226.78% -201.05% -53.55% Greenwich LifeSciences N/A -450.87%-333.18% Do insiders & institutionals believe in ZVRA or GLSI? 35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, ZVRA or GLSI? Zevra Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Which has stronger earnings and valuation, ZVRA or GLSI? Greenwich LifeSciences has lower revenue, but higher earnings than Zevra Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M27.70-$105.51M-$1.90-6.29Greenwich LifeSciencesN/AN/A-$15.79M-$1.26-8.48 SummaryZevra Therapeutics beats Greenwich LifeSciences on 11 of the 16 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.57M$2.97B$5.59B$9.02BDividend YieldN/A2.44%5.25%4.03%P/E Ratio-8.4621.5127.5220.21Price / SalesN/A256.10414.66171.34Price / CashN/A41.8337.0657.97Price / Book56.217.808.095.62Net Income-$15.79M-$55.05M$3.17B$248.50M7 Day Performance6.43%5.29%3.48%4.82%1 Month Performance10.79%3.81%3.69%7.34%1 Year Performance-32.28%5.58%33.83%21.46% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.4827 of 5 stars$10.68+1.2%$39.00+265.2%-32.0%$142.57MN/A-8.463ZVRAZevra Therapeutics2.7637 of 5 stars$11.27+15.7%$23.14+105.3%+111.1%$532.58M$23.61M-5.9320News CoverageAnalyst ForecastGap UpHigh Trading VolumeTYRATyra Biosciences1.7697 of 5 stars$9.61-3.9%$30.83+220.8%-43.9%$530.90MN/A-5.9020TSHATaysha Gene Therapies2.6935 of 5 stars$2.34-4.5%$8.20+250.4%+13.4%$525.92M$8.33M-6.88180OPTOpthea0.3919 of 5 stars$3.41+7.2%$1.33-60.9%+71.4%$524.84M$120K0.008Gap UpBCYCBicycle Therapeutics4.1543 of 5 stars$7.17-3.5%$25.00+248.7%-60.7%$514.56M$35.28M-2.28240KURAKura Oncology4.5448 of 5 stars$5.68-3.1%$24.50+331.3%-70.1%$507.33M$53.88M-2.70130SEPNSepterna1.1163 of 5 stars$10.85-4.6%$26.75+146.5%N/A$506.63M$1.08M0.00N/ANews CoverageABVXAbivax2.5643 of 5 stars$7.95-0.1%$31.00+289.9%-37.2%$505.10MN/A0.0061Positive NewsGap UpHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$503.67M$167.50M0.00121News CoverageAnalyst ForecastAnalyst RevisionPRMEPrime Medicine4.0646 of 5 stars$3.80+22.2%$10.08+165.4%-19.2%$498.92M$3.85M-1.85234Options VolumeHigh Trading Volume Related Companies and Tools Related Companies ZVRA Competitors TYRA Competitors TSHA Competitors OPT Competitors BCYC Competitors KURA Competitors SEPN Competitors ABVX Competitors MAZE Competitors PRME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
